BiotechTube

Leucovorin + 5-Fluorouracil + Aldoxorubicin HCl + nab-Paclitaxel + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6207 + GI-6301 + Avelumab + ALT-803 + haNK + Cyclophosphamide + Doxorubicin HCL + paclitaxel

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer (TNBC)

Conditions

Triple Negative Breast Cancer (TNBC)

Trial Timeline

Sep 1, 2018 → Feb 9, 2022

NCT ID
NCT03554109

About Leucovorin + 5-Fluorouracil + Aldoxorubicin HCl + nab-Paclitaxel + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6207 + GI-6301 + Avelumab + ALT-803 + haNK + Cyclophosphamide + Doxorubicin HCL + paclitaxel

Leucovorin + 5-Fluorouracil + Aldoxorubicin HCl + nab-Paclitaxel + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6207 + GI-6301 + Avelumab + ALT-803 + haNK + Cyclophosphamide + Doxorubicin HCL + paclitaxel is a phase 2 stage product being developed by ImmunityBio for Triple Negative Breast Cancer (TNBC). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03554109. Target conditions include Triple Negative Breast Cancer (TNBC).

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03554109Phase 2Withdrawn

Competing Products

20 competing products in Triple Negative Breast Cancer (TNBC)

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
eFT508eFFECTOR TherapeuticsPhase 2
44
No drugDaiichi SankyoPre-clinical
23
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
Abemaciclib + BicalutamideEli LillyPhase 2
52
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
77
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
65
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab + Nab paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
33
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
77
Combination of Veliparib + LapatinibAbbViePre-clinical
23
Capivasertib + ItraconazoleAstraZenecaPhase 1
33
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
52
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
41
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
33
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
77
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
52

Other Products from ImmunityBio

NAI + Pembrolizumab + NAI + Nivolumab + Ipilimumab + Pembrolizumab + NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel (Investigator's choice) + Cisplatin/carboplatin and pemetrexed plus pembrolizumab. + Cisplatin/carboplatin and pemetrexed plus atezolizumab. + Carboplatin and paclitaxel plus atezolizumab and bevacizumab. + Carboplatin and nab-paclitaxel plus atezolizumab. + NAI + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxelPhase 3
74
N-803 + Tislelizumab + DocetaxelPhase 3
74
Aldoxorubicin + Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)Phase 3
74
N-803 and BCG + N-803Phase 2/3
62
hAd5-S-Fusion+N-ETSD + Placebo (0.9% (w/v) saline)Phase 2/3
62